These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 7789097)

  • 1. Cross-resistance analysis for DU-6859a, a new fluoroquinolone, compared to six structurally similar compounds (ciprofloxacin, clinafloxacin, fleroxacin, levofloxacin, ofloxacin, and sparfloxacin).
    Cormican MG; Marshall SA; Jones RN
    Diagn Microbiol Infect Dis; 1995 Jan; 21(1):51-4. PubMed ID: 7789097
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cross-resistance analysis for clinafloxacin compared with ciprofloxacin, fleroxacin, ofloxacin, and sparfloxacin using a predictor panel of ciprofloxacin-resistant bacteria.
    Cormican MG; Jones RN
    J Antimicrob Chemother; 1995 Aug; 36(2):431-4. PubMed ID: 8522474
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activities of three investigational fluoroquinolones (BAY y 3118, DU-6859a, and clinafloxacin) against Neisseria gonorrhoeae isolates with diminished susceptibilities to ciprofloxacin and ofloxacin.
    Carlyn CJ; Doyle LJ; Knapp CC; Ludwig MD; Washington JA
    Antimicrob Agents Chemother; 1995 Jul; 39(7):1606-8. PubMed ID: 7492114
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro antibacterial activity of DU-6859a, a new fluoroquinolone.
    Nakane T; Iyobe S; Sato K; Mitsuhashi S
    Antimicrob Agents Chemother; 1995 Dec; 39(12):2822-6. PubMed ID: 8593031
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Comparative in vitro activities of DU-6859a, levofloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against 387 aerobic and anaerobic bite wound isolates.
    Goldstein EJ; Citron DM; Hunt Gerardo S; Hudspeth M; Merriam CV
    Antimicrob Agents Chemother; 1997 May; 41(5):1193-5. PubMed ID: 9145900
    [TBL] [Abstract][Full Text] [Related]  

  • 6. DU-6859a, a new fluoroquinolone agent. Comparative in vitro activity against enteric pathogens and multiresistant outpatient Escherichia coli.
    Tomayko JF; Korten V; Murray BE
    Diagn Microbiol Infect Dis; 1994 Sep; 20(1):45-7. PubMed ID: 7867298
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro activity of DU-6859a against anaerobic bacteria.
    Wexler HM; Molitoris E; Reeves D; Finegold SM
    Antimicrob Agents Chemother; 1994 Oct; 38(10):2504-9. PubMed ID: 7840599
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The effects of increasing levels of quinolone resistance on in-vitro activity of four quinolones.
    Thomson KS; Sanders CC
    J Antimicrob Chemother; 1998 Aug; 42(2):179-87. PubMed ID: 9738835
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Bactericidal activities of DU-6859a and clinafloxacin (CI-960) against staphylococci.
    Forstall GJ; Knapp CC; Washington JA
    Antimicrob Agents Chemother; 1994 Aug; 38(8):1868-70. PubMed ID: 7986024
    [TBL] [Abstract][Full Text] [Related]  

  • 10. In-vitro comparison of DU-6859a, a novel fluoroquinolone, with other quinolones and oral cephalosporins tested against 5086 recent clinical isolates.
    Marshall SA; Jones RN; Murray PR; Washington JA; Allen SD; Gerlach EH; Erwin ME
    J Antimicrob Chemother; 1993 Dec; 32(6):877-84. PubMed ID: 8144428
    [No Abstract]   [Full Text] [Related]  

  • 11. In vitro activity of quinupristin/dalfopristin and newer quinolones combined with gentamicin against resistant isolates of Enterococcus faecalis and Enterococcus faecium.
    Giamarellos-Bourboulis EJ; Sambatakou H; Grecka P; Giamarellou H
    Eur J Clin Microbiol Infect Dis; 1998 Sep; 17(9):657-61. PubMed ID: 9832270
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro susceptibility of anaerobes to quinolones in the United States.
    Hecht DW; Wexler HM
    Clin Infect Dis; 1996 Dec; 23 Suppl 1():S2-8. PubMed ID: 8953099
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cross-resistance and cross-susceptibility between fluoroquinolone agents.
    Barry AL; Fuchs PC
    Eur J Clin Microbiol Infect Dis; 1991 Dec; 10(12):1013-8. PubMed ID: 1666360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Postantibiotic effect of DU-6859a and levofloxacin as compared with ofloxacin.
    Houston AK; Jones RN
    Diagn Microbiol Infect Dis; 1994 Jan; 18(1):57-9. PubMed ID: 8026158
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Activity of two novel fluoroquinolones (DU-6859a and DV-7751a) tested against glycopeptide-resistant enterococcal isolates.
    Jones RN; Johnson DM; Biedenbach DJ; Marshall SA
    Diagn Microbiol Infect Dis; 1995 Nov; 23(3):123-7. PubMed ID: 8849658
    [TBL] [Abstract][Full Text] [Related]  

  • 16. In vitro activities of five quinolones against Chlamydia pneumoniae.
    Hammerschlag MR; Hyman CL; Roblin PM
    Antimicrob Agents Chemother; 1992 Mar; 36(3):682-3. PubMed ID: 1320366
    [TBL] [Abstract][Full Text] [Related]  

  • 17. In vitro and in vivo antimycobacterial activities of a new quinolone, DU-6859a.
    Saito H; Tomioka H; Sato K; Dekio S
    Antimicrob Agents Chemother; 1994 Dec; 38(12):2877-82. PubMed ID: 7695276
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The new 4-quinolones DU-6859a and DV-7751a show enhanced activity against Streptococcus pneumoniae.
    Morrissey I; Smith JT
    Drugs; 1995; 49 Suppl 2():228-9. PubMed ID: 8549312
    [No Abstract]   [Full Text] [Related]  

  • 19. Effect of growth conditions on antimicrobial activity of DU-6859a and its bactericidal activity determined by the killing curve method.
    Tanaka M; Hoshino K; Hohmura M; Ishida H; Kitamura A; Sato K; Hayakawa I; Nishino T
    J Antimicrob Chemother; 1996 Jun; 37(6):1091-102. PubMed ID: 8836812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative antimicrobial activity and spectrum of CP-99,219, a novel fluoroquinolone, tested against ciprofloxacin-resistant clinical isolates.
    Murphy SP; Cormican MG; Jones RN
    Ir J Med Sci; 1995; 164(4):271-3. PubMed ID: 8522427
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.